Bio-XL transforms innovative ideas and technologies into new diagnostics and treatments
BioXL actively scouts, develops, and in-license innovative technologies that translate into diagnostics, drugs, or treatments.
Target large patient populations with significant unmet needs.
Maintain contacts and engagement with pharma companies, in the relevant areas, from early development stages.
BioXL brought together scientific and business leaders who share a passion for innovating. Our team has vast experience in biological sciences and in managing business platforms.
Meir Azulay, MSc
Meir Azulay has several decades of experience in process development and manufacturing biopharmaceutical drugs in Merck-Serono (participated in the development and manufacturing of Rebif, a blockbuster for MS). MSc in biochemistry from the Hebrew University in Jerusalem.
Since 2005, Meir has founded and managed a CDMO company; He is co-founder of several startups in the fields of biopharma, food-tech, and biotech.
Avraham Laban, PhD
Dr. Avraham Laban has vast experience in drug development, enzyme production, and biochemical analysis. Avraham held research and teaching positions at MIT, Harvard, and Israel. Avraham has founded and managed a startup company in the field of Renewable Energy.
Avraham is co-founder of several startups in the fields of biopharma, food-tech, and biotech.
Ouri Fischel, Ph.D. MBA
Chief Operation Officer
Dr. Ouri Fischel has substantial experience in drug discovery.
Ouri has been involved with protein kinase inhibitors designed for cancer treatment in collaboration with Sanofi-Aventis and Janssen Pharmaceutica (J&J).
With Ph.D. studies in pharmacology and MBA in biomedical management, Ouri has acquired the necessary skills and experience in entrepreneurship and investment banking. Ouri has successfully raised funding for companies involved in Rational Drug Design, Cheminformatics, and Machine Learning.
Stephen Simes, BSc, MBA
Chairman of BioXL board
Mr. Stephen Simes is a Serial biopharmaceutical industry CEO/Board member experienced in the management, financing and governance of public biopharma companies with FDA-approved and R&D-stage products, many of which received FDA-approval. Having raised over $500 million for his companies in financing transactions, product licensing and M & A transactions.
Prof. Ido Wolf, MD/PhD
Clinical and Scientific Advisor- Oncology
Prof. Ido Wolf is the Oncology Division Head, Endocrine-Oncology Laboratory Head – Tel Aviv Sourasky Medical Center. One of the leaders in Klotho research and development, worldwide
Prof. Shai Efrati, MD/PhD
Clinical and Scientific Advisor- Kidney and Longevity
Prof. Shai Efrati is a Nephrologist, Director of the Sagol center for hyperbaric medicine and research at Assaf-Harofeh Medical Center in Israel (The largest most occupied hyperbaric center worldwide). Director of R&D of Assaf-Harofeh Medical center, affiliated to Tel-Aviv University
Mazal Dahan, PhD
Dr. Mazal Dahan is PhD Chemistry graduated (Hebrew University), with Post Doc at John-Hopkins, Baltimore, MD.
Mazal held Managing positions, R&D and manufacturing in biotech and pharma; CSO and CEO is start-up developing parenteral compound from product design to GMP production and registration.
Mazal's Expertise: Product development, formulation, pre-clinical studies, process development, analytical methods.